Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70.

Article  PubMed  Google Scholar 

Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.

Article  CAS  PubMed  Google Scholar 

Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545.

Article  PubMed  PubMed Central  Google Scholar 

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251.

Article  PubMed  Google Scholar 

Kampylafka E, Simon D, d’Oliveira I, Linz C, Lerchen V, Englbrecht M, et al. Disease interception with Interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178.

Article  PubMed  PubMed Central  Google Scholar 

Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017;56(8):1251–3.

PubMed  Google Scholar 

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-Interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–31.

Article  CAS  PubMed  Google Scholar 

Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79.

Article  PubMed  PubMed Central  Google Scholar 

Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407–13.

Article  PubMed  Google Scholar 

Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024. https://doi.org/10.1136/rmdopen-2023-004062.

Article  PubMed  PubMed Central  Google Scholar 

Jadon DR, Corp N, van der Windt DA, Coates LC, Soriano ER, Kavanaugh A, et al. Management of concomitant inflammatory bowel disease or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):438–50.

CAS  PubMed  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.

Article  CAS  PubMed  Google Scholar 

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.

Article  CAS  PubMed  Google Scholar 

Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med. 2009;361(5):496–509.

Article  CAS  PubMed  Google Scholar 

McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482–91.

Article  PubMed  Google Scholar 

Mease PJ, Genovese M, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, et al. Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from PSA study M02-537. Ann Rheum Dis. 2007;66:419.

Google Scholar 

van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73(1):233–7.

Article  PubMed  Google Scholar 

van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019;78(5):610–6.

Article  PubMed  Google Scholar 

Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415–29.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019;46(9):1089–96.

Article  PubMed  Google Scholar 

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.

Article  PubMed  PubMed Central  Google Scholar 

Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates LC, Rednic S, et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther. 2023;25(1):56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–22.

Article  CAS  PubMed  Google Scholar 

Schakel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016–27.

Article  CAS  PubMed  Google Scholar 

Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang XY, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750–63.

Article  CAS  PubMed  Google Scholar 

Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lobao B, Lourenco D, Giga A, Mendes-Bastos P. From PsO to PsA: the role of T(RM) and Tregs in psoriatic disease, a systematic review of the literature. Front Med. 2024;11:1346757.